Dan Werb

PhD

Scientist, Li Ka Shing Knowledge Institute

Email: dwerb@ucsd.edu
Tel: 858-205-8262
Twitter: @dmwerb

Biography

Dan Werb, PhD, is an epidemiologist and policy analyst with expertise in Human Immunodeficiency Virus (HIV), addictions, and drug policy. Dr. Werb is a Research Scientist at the Li Ka Shing Knowledge Institute (LKSKI) at St. Michael’s Hospital in Toronto. He is also an Assistant Professor in the Division of Global Public Health at the University of California, San Diego, where he is Principal Investigator of PRIMER: Preventing Injecting by Modifying Existing Responses, a five-year multi-site cohort study tasked with developing interventions to preventing entry into injection drug use. This study is funded through the inaugural United States National Institute on Drug Abuse Avenir Award, a USD$1.5 million research grant for creative new investigators proposing highly innovative research at the intersection of HIV and substance use. At the LKSKI, Dr. Werb is Director and Scientific Board Chair of the International Centre for Science in Drug Policy (ICSDP; www.icsdp.org), a recognized global leader in cutting edge policy research and communications. Dr. Werb has published dozens of studies on issues related to health policy and addictions, with a focus on preventing the transition of street youth into injection drug use, as well as on identifying the impact of policy and public health interventions on street-based drug-using populations. At the ICSDP, Dr. Werb is a sought after source of expertise on drug policy, and has appeared in media related to his work in every global hemisphere. He has helped oversee communications campaigns around such high profile projects as the Vienna Declaration (www.viennadeclaration.com). He has also published extensively on global drug policy and HIV policy. Dr. Werb is a former Trudeau Foundation Scholar and a Canadian Institutes of Health Research postdoctoral fellow. He conducts extensive knowledge translation on drug policy and public health, through print and radio journalism, and is the winner of a 2014 Canadian National Magazine Award for his popular science writing.

Please note: Dr. Werb is not taking any summer students in 2018.

Recent Publications

  1. Meyers, SA, Smith, LR, Luisa Mittal, M, Strathdee, SA, Garfein, RS, Guise, A et al.. The role of gender and power dynamics in injection initiation events within intimate partnerships in the US-Mexico border region. Cult Health Sex. 2019; :1-16. doi: 10.1080/13691058.2019.1651903. PubMed PMID:31625809 .
  2. Lake, S, Kerr, T, Werb, D, Haines-Saah, R, Fischer, B, Thomas, G et al.. Guidelines for public health and safety metrics to evaluate the potential harms and benefits of cannabis regulation in Canada. Drug Alcohol Rev. 2019;38 (6):606-621. doi: 10.1111/dar.12971. PubMed PMID:31577059 .
  3. Mittal, ML, Guise, A, Rafful, C, Gonzalez-Zuñiga, P, Davidson, P, Vashishtha, D et al.. "Another Person Was Going to Do It": The Provision of Injection Drug Use Initiation Assistance in a High-Risk U.S.-Mexico Border Region. Subst Use Misuse. 2019; :1-13. doi: 10.1080/10826084.2019.1648514. PubMed PMID:31389282 .
  4. Olding, M, Werb, D, Guise, A, Small, W, McNeil, R. Navigating social norms of injection initiation assistance during an overdose crisis: A qualitative study of the perspectives of people who inject drugs (PWID) in Vancouver, Canada. Int. J. Drug Policy. 2019;69 :24-33. doi: 10.1016/j.drugpo.2019.04.004. PubMed PMID:31029914 .
  5. Reddon, H, Fast, D, DeBeck, K, Werb, D, Hayashi, K, Wood, E et al.. Prevalence and correlates of selling illicit cannabis among people who use drugs in Vancouver, Canada: A ten-year prospective cohort study. Int. J. Drug Policy. 2019;69 :16-23. doi: 10.1016/j.drugpo.2019.02.006. PubMed PMID:31015080 .
  6. Mittal, ML, Jain, S, Sun, S, DeBeck, K, Milloy, MJ, Hayashi, K et al.. Opioid agonist treatment and the process of injection drug use initiation. Drug Alcohol Depend. 2019;197 :354-360. doi: 10.1016/j.drugalcdep.2018.12.018. PubMed PMID:30922483 PubMed Central PMC6719710.
  7. Bórquez, A, Garfein, RS, Abramovitz, D, Liu, L, Beletsky, L, Werb, D et al.. Prevalence and Correlates of Injecting with Visitors from the United States Among People Who Inject Drugs in Tijuana, Mexico. J Immigr Minor Health. 2019; :. doi: 10.1007/s10903-019-00868-8. PubMed PMID:30771144 PubMed Central PMC6697237.
  8. Meyers, SA, Scheim, A, Jain, S, Sun, X, Milloy, MJ, DeBeck, K et al.. Gender differences in the provision of injection initiation assistance: a comparison of three North American settings. Harm Reduct J. 2018;15 (1):59. doi: 10.1186/s12954-018-0270-6. PubMed PMID:30514384 PubMed Central PMC6280353.
  9. Goodman-Meza, D, Medina-Mora, ME, Magis-Rodríguez, C, Landovitz, RJ, Shoptaw, S, Werb, D et al.. Where Is the Opioid Use Epidemic in Mexico? A Cautionary Tale for Policymakers South of the US-Mexico Border. Am J Public Health. 2018; :e1-e10. doi: 10.2105/AJPH.2018.304767. PubMed PMID:30495992 PubMed Central PMC6301408.
  10. Rafful, C, Jain, S, Sun, X, Strathdee, SA, Garfein, RS, Cuevas-Mota, J et al.. Identification of a Syndemic of Blood-Borne Disease Transmission and Injection Drug Use Initiation at the US-Mexico Border. J. Acquir. Immune Defic. Syndr. 2018;79 (5):559-565. doi: 10.1097/QAI.0000000000001858. PubMed PMID:30222661 PubMed Central PMC6231973.
Search PubMed

Affiliations & Other Activities

  • Assistant Professor, Division of Global Public Health, University of California San Diego Director, International Centre for Science in Drug Policy
X